Weight Loss Drugs and Pancreatitis: Why Pharmacovigilance Matters More Than Ever

The rise of GLP-1 receptor agonists such as semaglutide and tirzepatide has redefined the landscape of metabolic medicine. With proven efficacy in type 2 diabetes and obesity, so-called weight loss drugs are now being prescribed at unprecedented rates.

Yet as their popularity grows, so does regulatory and safety scrutiny – especially around an evolving signal: acute pancreatitis, which has recently been highlighted by both the MHRA and FDA and in 2023 by a research paper published in the British Medical Journal linking GLP-1 drugs to an increased risk of gastrointestinal events, including pancreatitis, gastroparesis, and bowel obstruction (BMJ 2023;383:p2330).

The Signal: Pancreatitis and GLP-1 Receptor Agonists

Concerns about pancreatic safety with GLP-1s aren't new. The signal first emerged over a decade ago: Exenatide (Byetta) was the first GLP-1 agonist approved (2005) and reports of acute pancreatitis began emerging shortly thereafter. The FDA responded by requesting label revisions to include pancreatitis in the "Precautions" section; a drug safety communication was released in 2013 and box warnings were issued clarifying that exenatide must be discontinued if pancreatitis is suspected.

Liraglutide (Victoza) was approved later (EU 2009, US 2010). Though initial trials suggested a low pancreatitis risk, post-marketing experience told a different story, and label revisions recommended that liraglutide be discontinued upon suspicion of pancreatitis; clinicians were advised to exercise caution in patients with a history of pancreatitis.

In 2013, the European Medicines Agency (EMA) launched a formal review under Article 5(3), prompted by academic findings of pancreatic inflammation and ductal metaplasia in patients treated with GLP-1 agonists and DPP-4 inhibitors. After evaluating all available non-clinical, clinical, and post-marketing data, the CHMP concluded there was no confirmed increased risk, and that current warnings were adequate. The review called for harmonised labelling across the GLP-1/DPP-4 class and ongoing monitoring and further large-scale safety studies.

Since 2021, as GLP-1s gained regulatory approval for obesity and off-label cosmetic weight loss use expanded, the safety landscape for these medications has shifted.

Real-World Data Highlights a Growing Concern

While clinical trials have generally not demonstrated a statistically significant increase in pancreatitis risk with GLP-1 receptor agonists, real-world pharmacovigilance data tells a more nuanced story – particularly as prescribing expands to broader and sometimes lower-risk populations.

Data from the Medicines and Healthcare Products Regulatory Agency (MHRA) show that hundreds of cases of acute and chronic pancreatitis, including 10 deaths, have been reported in people taking these drugs. The UK MHRA received nearly 400 Yellow Card reports of acute pancreatitis linked to GLP-1s by 2025:

• Tirzepatide: >180 reports, 5 deaths
• Semaglutide: >100 reports, 1 fatal necrotising case

Similar patterns are seen in FDA FAERS data, with suggestions of a dose-response relationship and increased risk tied to treatment duration and dose escalation.

Genetic Susceptibility: The Next Chapter in Signal Management

In June 2025, the MHRA and Genomics England launched the Yellow Card Biobank, which aims to collect DNA from patients who experienced serious adverse reactions – including pancreatitis following GLP-1 use. The goal is to identify genetic variants that may predispose certain patients to increased risk. This move could enable personalised pharmacovigilance, marking a shift from reactive reporting to predictive risk profiling.

While all medicines inherently carry risks, safe and effective therapeutic use lies in continuously assessing the benefit-risk balance – and understanding that this balance can shift depending on the population, indication, and context of use.

For GLP-1 receptor agonists, the benefit-risk profile remains strongly favourable within their licensed indications. In patients with type 2 diabetes, these drugs deliver significant glycaemic control, weight loss, and even cardiovascular protection in high-risk subgroups. In those with obesity, sustained weight reductions of 15–22%, along with improvements in lipid levels, blood pressure, and quality of life, support their use despite rare but known risks such as pancreatitis.

However, the picture becomes more complex in the context of off-label or unsupervised use. The growing trend of prescribing GLP-1s to young adults without obesity-related comorbidities (so-called "Skinny Jabs"), for cosmetic weight loss, or via unregulated compounded formulations raises serious pharmacovigilance concerns. In these lower-risk groups, where baseline disease burden is minimal, the tolerance for serious adverse events like pancreatitis – even if rare – is significantly reduced.

These evolving patterns challenge regulators, Marketing Authorisation Holders, and healthcare professionals to ask:

• Does the therapeutic benefit in these populations justify the risk?
• Are appropriate monitoring strategies and safeguards in place?
• Should safety communications, Risk Management Plans, and/or labelling updates evolve to reflect this expanded real-world usage?

The risk-benefit equation is not static. Ongoing pharmacovigilance, data-driven evaluation, and proactive regulatory engagement are essential to protect patient safety – particularly as usage extends beyond the populations originally studied.

How regenold Can Support You

We offer expert pharmacovigilance solutions tailored to your product portfolio, including therapeutic areas like metabolic disease:

• Signal Management: End-to-end detection, validation, and risk assessment
• Aggregate Safety Reporting: Robust DSURs, PSURs/PBRERs, and narrative case analyses
• Risk–Benefit Consulting: Evidence-based reviews to support internal decision-making and external communication
• Regulatory Strategy: Global alignment with MHRA, EMA, FDA, and evolving PV frameworks

Whether you are launching your first GLP-1 agent or managing an established portfolio, our team is here to help you navigate this dynamic landscape with confidence and clarity.